Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

showed that olaparib (Lynparza), a PARP inhibitor, significantly improved overall survival in patients with BRCA-mutated, HER2-negative early breast cancer. This marks the first PARP inhibitor to show ...

Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, exhibited clinically meaningful improvements in overall survival, among other ...

“These data reinforce the importance of germline BRCA testing at the time of diagnosis, so we can identify all eligible patients who may benefit from treatment with olaparib as early as possible ...

Merck & Co – known as MSD outside of the US and Canada – has shared positive results from a late-stage trial of a Keytruda (pembrolizumab)/Lynparza (olaparib) regimen as a first-line treatment for ...

AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced long-term results from the OlympiA phase 3 trial which showed Lynparza (olaparib) demonstrated sustained, ...